- PLN1.31bn
- PLN1.22bn
- PLN216.57m
Annual balance sheet for Celon Pharma SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | Interim Report | ARS | ARS | ARS |
Standards: | PAS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 66.7 | 44 | 228 | 165 | 115 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 45.5 | 41 | 27.2 | 33.7 | 48.2 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 144 | 119 | 279 | 238 | 190 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 243 | 331 | 329 | 342 | 334 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 591 | 532 | 707 | 643 | 569 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 26 | 114 | 86.4 | 116 | 86.3 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 146 | 187 | 153 | 163 | 124 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 445 | 345 | 554 | 480 | 446 |
Total Liabilities & Shareholders' Equity | 591 | 532 | 707 | 643 | 569 |
Total Common Shares Outstanding |